Abrocitinib for atopic dermatitis

Affiliations

¹ Albany Medical College, Albany, NY, USA.
² Medical College of Georgia at Augusta University, Augusta, GA, USA.
³ Loma Linda School of Medicine, Loma Linda, CA, USA.
⁴ Dermatology Research and Education Foundation, Irvine, CA 92620, USA. Electronic address: jashinwu@gmail.com.

Comment

Shelley K Uppal et al. Lancet. 2021.

. 2021 Jan 16;397(10270):195-196.

doi: 10.1016/S0140-6736(21)00036-2.

¹ Albany Medical College, Albany, NY, USA.
² Medical College of Georgia at Augusta University, Augusta, GA, USA.
³ Loma Linda School of Medicine, Loma Linda, CA, USA.
⁴ Dermatology Research and Education Foundation, Irvine, CA 92620, USA. Electronic address: jashinwu@gmail.com.

No abstract available

Comment in

Abrocitinib for atopic dermatitis - Authors' reply.
Simpson EL, Bieber T, Thyssen JP, Valdez H, Rojo R. Simpson EL, et al. Lancet. 2021 Jan 16;397(10270):196. doi: 10.1016/S0140-6736(21)00037-4. Lancet. 2021. PMID: 33453780 No abstract available.

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, Bieber T, Thyssen JP, Yosipovitch G, Flohr C, Magnolo N, Maari C, Feeney C, Biswas P, Tatulych S, Valdez H, Rojo R. Simpson EL, et al. Lancet. 2020 Jul 25;396(10246):255-266. doi: 10.1016/S0140-6736(20)30732-7. Lancet. 2020. PMID: 32711801 Clinical Trial.